Opinion|Videos|August 14, 2025
Exploring Recent Developments in The Treatment of Prostate Cancer
Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact clinical decision-making in prostate cancer treatment, emphasizing the importance of quality of life data and the shift from using ADT alone as standard care toward combination therapies in prostate cancer management.
Advertisement
Episodes in this series
1:56-4:02 - Importance of trial design in therapy selection
4:02-8:09 - Benefits of cooperative trials and comparison of trial end points
8:09-12:10 - Applicability of trial inclusion criteria in daily practice
12:10-13:17 - Moving away from ADT monotherapy as a comparator and applicability of subset analysis
13:17-16:08 - Evaluating the relevance of a clinical trial
16:08-18:59 - Translating statistical significance, biomarker analysis, and subgroup analysis to the clinic
18:59-22:34 - Use of rPFS in informing clinical decisions
22:34-26:56 - Evaluation of patients with conventional imaging and PSMA PET
26:56-31:14 - Importance of quality of life data in clinical trials
31:14-34:34 - Importance of trial design in evaluating a therapy
34:34-37:22 - Patient selection for triplet therapy
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
